Development of an ionic liquid-based dispersive liquid–liquid microextraction method for the determination of nifurtimox and benznidazole in human plasma [PDF]
Talanta, 2013 Dispersive ionic liquid–liquid microextraction combined with liquid chromatography and UV detection was used for the determination of two antichagasic drugs in human plasma: nifurtimox and benznidazole.
Facundo Garcia-Bournissen
exaly +4 more sources
Antitrypanosomal therapy for Chagas disease: A single center experience with adverse drug reactions and strategies for enhancing treatment completion. [PDF]
PLoS Neglected Tropical DiseasesAnti-trypanosomal therapy is generally recommended for individuals under age 50 with the indeterminate form of Chagas disease to prevent disease progression. However, benznidazole and nifurtimox are associated with adverse drug reactions.
Katherine Reifler +13 more
doaj +2 more sources
Development and Characterization of Innovative Nifurtimox Formulations as Therapeutic Alternative for Chagas Disease [PDF]
Tropical Medicine and Infectious DiseaseChagas disease, caused by Trypanosoma cruzi, remains a neglected tropical disease with limited and often suboptimal chemotherapeutic treatment options.
Ana Lia Mazzeti +4 more
doaj +2 more sources
Redefining the treatment of Chagas disease: a review of recent clinical and pharmacological data for a novel formulation of nifurtimox. [PDF]
PLoS Neglected Tropical DiseasesNifurtimox has been used for over 50 years to treat patients with Chagas disease, a potentially life-threatening neglected tropical disease caused by the protozoan parasite Trypanosoma cruzi.
Jaime Altcheh +4 more
doaj +2 more sources
3D-Printed Tablets of Nifurtimox: In Vitro and In Vivo Anti-Trypanosoma cruzi Studies [PDF]
PharmaceuticsBackground/Objectives: Chagas disease is a neglected tropical disease caused by infection with the parasite Trypanosoma cruzi. Benznidazole and nifurtimox are the only approved drugs for treating this condition, but their low aqueous solubility may lead ...
Giselle R. Bedogni +6 more
doaj +2 more sources
Concomitant diagnosis of Trypanosoma cruzi and HIV in a patient with neurologic manifestations: A case report [PDF]
Brazilian Journal of Infectious DiseasesAmerican trypanosomiasis or Chagas disease is a vector-borne infection caused by the protozoan parasite Trypanosoma cruzi, characterized by acute and chronic phases; reactivations due to immunosuppression can occur.
Emmanuel Molina Solano +4 more
doaj +2 more sources
In-hospital safety in field conditions of Nifurtimox Eflornithine Combination Therapy (NECT) for T. B. Gambiense Sleeping Sickness [PDF]
, 2012 Trypanosoma brucei (T.b.) gambiense Human African trypanosomiasis (HAT; sleeping sickness) is a fatal disease. Until 2009, available treatments for 2(nd) stage HAT were complicated to use, expensive (eflornithine monotherapy), or toxic, and ...
A Stanghellini +31 more
core +31 more sources
Frontiers in Cellular and Infection Microbiology, 2022 Trypanosoma cruzi is the causative agent of Chagas disease which is currently treated by nifurtimox (NFX) and benznidazole (BZ). Nevertheless, the mechanism of action of NFX is not completely established.
Gabriela Specker +3 more
doaj +1 more source
Frontiers in Parasitology, 2023 Determining the success of antitrypanosomal therapy for Chagas disease is challenging, particularly in the chronic phase of the disease, because seropositivity persists for a long time after successful antitrypanosomal treatment and is known to be ...
Ulrike Grossmann, Maria-Luisa Rodriguez
doaj +1 more source
PLoS Neglected Tropical Diseases, 2021 Nifurtimox is indicated in Chagas disease but determining its effectiveness in chronic disease is hindered by the length of time needed to demonstrate negative serological conversion. We manually reviewed long-term follow-up data from hospital records of
David Vizcaya +8 more
doaj +1 more source